Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated Dementia

• Published in: PLoS pathogens Vol. 5; no. 4; p. e1000395
• Main Authors: Schnell, Gretja, Spudich, Serena, Harrington, Patrick, Price, Richard W., Swanstrom, Ronald
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.04.2009; Public Library of Science (PLoS)
• Subjects: AIDS Dementia Complex - pathology; AIDS Dementia Complex - virology; Antiretroviral drugs; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Blood - virology; Brain; CD4-Positive T-Lymphocytes - pathology; CD4-Positive T-Lymphocytes - virology; Cellular Senescence; Central nervous system; Central Nervous System - virology; Cerebrospinal Fluid - virology; Dementia; Drug therapy; Experiments; Genetic aspects; Genetic Variation; Half-Life; Health aspects; HIV; HIV (Viruses); HIV Infections - complications; HIV Infections - pathology; HIV Infections - virology; HIV-1 - genetics; Human immunodeficiency virus; Humans; Infections; Leukocytosis; Macrophages - pathology; Macrophages - virology; Neurological Disorders/Infectious Diseases of the Nervous System; Physiological aspects; Plasma; Risk factors; Studies; T cells; Virology/Immunodeficiency Viruses; United States
• ISSN: 1553-7374; 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1000395

Human immunodeficiency virus type 1 (HIV-1) invades the central nervous system (CNS) shortly after systemic infection and can result in the subsequent development of HIV-1-associated dementia (HAD) in a subset of infected individuals. Genetically compartmentalized virus in the CNS is associated with HAD, suggesting autonomous viral replication as a factor in the disease process. We examined the source of compartmentalized HIV-1 in the CNS of subjects with HIV-1-associated neurological disease and in asymptomatic subjects who were initiating antiretroviral therapy. The heteroduplex tracking assay (HTA), targeting the variable regions of env, was used to determine which HIV-1 genetic variants in the cerebrospinal fluid (CSF) were compartmentalized and which variants were shared with the blood plasma. We then measured the viral decay kinetics of individual variants after the initiation of antiretroviral therapy. Compartmentalized HIV-1 variants in the CSF of asymptomatic subjects decayed rapidly after the initiation of antiretroviral therapy, with a mean half-life of 1.57 days. Rapid viral decay was also measured for CSF-compartmentalized variants in four HAD subjects (t(1/2) mean = 2.27 days). However, slow viral decay was measured for CSF-compartmentalized variants from an additional four subjects with neurological disease (t(1/2) range = 9.85 days to no initial decay). The slow decay detected for CSF-compartmentalized variants was not associated with poor CNS drug penetration, drug resistant virus in the CSF, or the presence of X4 virus genotypes. We found that the slow decay measured for CSF-compartmentalized variants in subjects with neurological disease was correlated with low peripheral CD4 cell count and reduced CSF pleocytosis. We propose a model in which infiltrating macrophages replace CD4(+) T cells as the primary source of productive viral replication in the CNS to maintain high viral loads in the CSF in a substantial subset of subjects with HAD.